litlas
ログインアカウント作成

Thomas J. Kipps

1979–2025 年に発表

251
論文数
66,939
被引用数
125
h 指数
245
i10 指数

被引用数

Thomas J. Kipps の年別被引用数1975 年: 被引用 1 件1978 年: 被引用 1 件1979 年: 被引用 4 件1980 年: 被引用 6 件1981 年: 被引用 2 件1982 年: 被引用 1 件1983 年: 被引用 3 件1985 年: 被引用 3 件1986 年: 被引用 6 件1987 年: 被引用 5 件1988 年: 被引用 21 件1989 年: 被引用 21 件1990 年: 被引用 26 件1991 年: 被引用 25 件1992 年: 被引用 40 件1993 年: 被引用 36 件1994 年: 被引用 55 件1995 年: 被引用 33 件1996 年: 被引用 43 件1997 年: 被引用 40 件1998 年: 被引用 66 件1999 年: 被引用 74 件2000 年: 被引用 83 件2001 年: 被引用 79 件2002 年: 被引用 121 件2003 年: 被引用 203 件2004 年: 被引用 195 件2005 年: 被引用 293 件2006 年: 被引用 437 件2007 年: 被引用 571 件2008 年: 被引用 818 件2009 年: 被引用 818 件2010 年: 被引用 792 件2011 年: 被引用 707 件2012 年: 被引用 697 件2013 年: 被引用 680 件2014 年: 被引用 589 件2015 年: 被引用 646 件2016 年: 被引用 604 件2017 年: 被引用 668 件2018 年: 被引用 671 件2019 年: 被引用 2,058 件2020 年: 被引用 2,379 件2021 年: 被引用 2,113 件2022 年: 被引用 1,549 件2023 年: 被引用 1,041 件2024 年: 被引用 1,790 件2025 年: 被引用 702 件2026 年: 被引用 26 件1976〜1977 年は被引用が無いため表示していません1984 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,662 件、この内訳の 29%中国: 引用元論文 2,013 件、この内訳の 10.3%ドイツ: 引用元論文 1,231 件、この内訳の 6.3%イタリア: 引用元論文 1,223 件、この内訳の 6.3%イギリス: 引用元論文 1,132 件、この内訳の 5.8%フランス: 引用元論文 679 件、この内訳の 3.5%オーストラリア: 引用元論文 632 件、この内訳の 3.2%スペイン: 引用元論文 577 件、この内訳の 2.9%カナダ: 引用元論文 480 件、この内訳の 2.4%日本: 引用元論文 461 件、この内訳の 2.4%オランダ: 引用元論文 422 件、この内訳の 2.2%インド: 引用元論文 391 件、この内訳の 2%
0%29%その他 23.7%

機関

分野

  • Biochemistry, Genetics and Molecular Biology45.8%
  • Medicine45.4%
  • Immunology and Microbiology6.2%
  • Computer Science0.5%
  • Engineering0.5%
  • Neuroscience0.3%
  • その他1.3%

トピック

  • MicroRNA in disease regulation8.5%
  • Chronic Lymphocytic Leukemia Research8.4%
  • Cancer-related molecular mechanisms research5.5%
  • Lymphoma Diagnosis and Treatment5%
  • Circular RNAs in diseases4.8%
  • RNA modifications and cancer3.1%
  • その他64.7%

共著者

全論文

検索で開く
  1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    著者: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, Thomas J. Kipps - Blood 2018 被引用: 1,689

  2. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    著者: Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour - New England Journal of Medicine 2015 被引用: 1,884

  3. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

    著者: George A. Calin, Calin Dan Dumitru, Masayoshi Shimizu, Roberta Bichi, Simona Zupo, Evan Noch, Hansjuerg Aldler, Sashi Rattan, Michael J. Keating, Kanti Rai, Laura Z. Rassenti, Thomas J. Kipps, Massimo Negrini, Florencia Bullrich, Carlo M. Croce - National Academy of Sciences, Proceedings of the National Academy of Sciences 2002 被引用: 5,018

  4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    著者: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 被引用: 1,562

  5. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    著者: Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna‐Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova, A. M. Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Sebastian Böettcher, Eugen Tausch, Rod Humerickhouse, Barbara Eichhorst, Clemens‐Martin Wendtner, Anton W. Langerak, Karl-Anton Kreuzer, Matthias Ritgen, Valentin Goede, Stephan Stilgenbauer, Mehrdad Mobasher, Michael Hallek - New England Journal of Medicine 2019 被引用: 852

  6. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    著者: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, John F. Gerecitano, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A. Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P. Kater - New England Journal of Medicine 2018 被引用: 909

  7. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    著者: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 被引用: 269

  8. miR-15 and miR-16 induce apoptosis by targeting BCL2

    著者: Amelia Cimmino, George A. Calin, Muller Fabbri, Marilena V. Iorio, Manuela Ferracin, Masayoshi Shimizu, Sylwia E. Wojcik, Rami I. Aqeilan, Simona Zupo, Mariella Dono, Laura Z. Rassenti, Hansjüerg Alder, Stefano Volinia, Chang‐Gong Liu, Thomas J. Kipps, Massimo Negrini, Carlo M. Croce - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 被引用: 3,521

  9. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

    著者: Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia - Blood 2022 被引用: 238

  10. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    著者: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 被引用: 1,617

  11. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    著者: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 被引用: 473

  12. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

    著者: William G. Wierda, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Stephen Opat, Alessandra Tedeschi, Xavier C. Badoux, Bryone J. Kuss, Sharon Jackson, Carol Moreno, Ryan Jacobs, John M. Pagel, Ian W. Flinn, Yvonne Pak, Cathy Zhou, Edith Szafer‐Glusman, Joi Ninomoto, James P. Dean, Danelle F. James, Paolo Ghia, Constantine S. Tam - Journal of Clinical Oncology 2021 被引用: 229

  13. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    著者: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 被引用: 1,684

  14. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    著者: Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, William G. Wierda, Thomas J. Kipps, Seong Lin Khaw, Dennis Carney, Simon He, David C.S. Huang, Hao Xiong, Yue Cui, Todd Busman, Evelyn McKeegan, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse - Journal of Clinical Oncology 2011 被引用: 818

  15. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    著者: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori A. Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod Humerickhouse, Gary Gordon, John F. Gerecitano - Journal of Clinical Oncology 2017 被引用: 751

  16. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    著者: Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris‐Cappio, Guillaume Dighiero, Hartmut Döhner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Kanti R. Rai, Thomas J. Kipps - Blood 2008 被引用: 3,193

  17. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

    著者: Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, Arijit Sinha, Anna‐Maria Fink, Sandra Robrecht, Olga Samoylova, Anna Marina Liberati, Javier Pinilla‐Ibarz, Stephen Opat, Liliya Sivcheva, Katell Le Dû, Laura Fogliatto, Carsten Utoft Niemann, Robert Weinkove, Sue Robinson, Thomas J. Kipps, Eugen Tausch, William Schary, Matthias Ritgen, Clemens‐Martin Wendtner, Karl-Anton Kreuzer, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Kirsten Fischer - The Lancet Oncology 2020 被引用: 327

  18. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    著者: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, James D’Rozario, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater - Blood 2022 被引用: 151

  19. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    著者: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 被引用: 463

  20. cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies

    著者: Christina B. Pedersen, Søren Helweg Dam, Mike Bogetofte Barnkob, Michael D. Leipold, Noelia Purroy, Laura Z. Rassenti, Thomas J. Kipps, Jennifer P. Nguyen, James A. Lederer, Satyen H. Gohil, Catherine J. Wu, Lars Rønn Olsen - Nature Communications 2022 被引用: 126

  21. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

    著者: Arnon P. Kater, Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline, Carolyn Owen, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Julie Dubois, Eric Eldering, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Su Young Kim, Brenda Chyla, Elizabeth A. Punnoose, Christopher R. Bolen, Zoe J. Assaf, Yanwen Jiang, Jue Wang, Marcus Lefebure, Michelle Boyer, Kathryn Humphrey, John F. Seymour - Journal of Clinical Oncology 2020 被引用: 220

  22. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    著者: Binyamin A. Knisbacher, Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylor‐Weiner, Pablo Bousquets‐Muñoz, Ander Díaz‐Navarro, Andrew Dunford, Shankara Anand, Helene Kretzmer, Jesús Gutiérrez‐Abril, Sara López-Tamargo, Stacey M. Fernandes, Clare Sun, Mariela Sivina, Laura Z. Rassenti, Christof Schneider, Shuqiang Li, Laxmi Parida, Alexander Meissner, François Aguet, Jan A. Burger, Adrian Wiestner, Thomas J. Kipps, Jennifer R. Brown, Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 被引用: 148

  23. ROR1: an orphan becomes apparent

    著者: Thomas J. Kipps - Blood 2022 被引用: 82

  24. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

    著者: Michael Y. Choi, George F. Widhopf, Emanuela M. Ghia, Reilly L. Kidwell, Md Kamrul Hasan, Jian Yu, Laura Z. Rassenti, Liguang Chen, Yun Chen, Emily Pittman, Minya Pu, Karen Messer, Charles Prussak, Januario E. Castro, Catriona Jamieson, Thomas J. Kipps - Cell stem cell 2018 被引用: 187